Polymeric benzyl carbonate-derivatives

1. A compound of Formula I:

wherein Y is an activating group;

X is selected from the group consisting of O, S and NR 3 ;

n is 1, or 2;

POLYMER is a water soluble, non-peptidic polymer wherein POLYMER does not comprise a poly(alkylene glycol);

R 1 , and R 2 , are independently selected from the group consisting of hydrogen, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkylenearyl, and aryl with the proviso that at least one of R 1 , and R 2 , is different from hydrogen; and

R 3 , is selected from the group consisting of hydrogen, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkylenearyl, and aryl.

2. The compound according to claim 1 , wherein POLYMER is selected from the group consisting of polyvinylpyrrolidone, poloxamer, polysaccharide, polysialic acid, hydroxyethyl starch, icodextrin, chondroitin sulfate, dermatan sulfate, heparin, chitosan, hyaluronic acid, dextran, dextran sulfate, and pentosan polysulfate.

3. The compound according to claim 1 , wherein R 1 , and R 2 , are independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl and n-butyl.

4. The compound according to claim 3 , wherein R 1 is hydrogen and R 2 , is methyl.

5. The compound according to claim 1 , wherein Y is selected from the group consisting of halide, —N 3 , —CN, RO—, NH 2 O—, NHRO—, NR 2 O—, RCO 2 —, ROCO 2 —, RNCO 2 —, RS—, RC(S)O—, RCS 2 —, RSC(0)S—, RSCS 2 —RSCO 2 —, ROC(S)O—, ROCS 2 —, RSO 2 —, RSO 3 —, ROSO 2 —, ROSO 3 —, RPO 3 —, ROPO 3 —, imidazolyl, N-triazolyl, N-benzotriazolyl, benzotriazolyloxy, imidazolyloxy, N-imidazolinone, N-imidazolone, N-imidazolinethione, N-succinimidyl, N-phthalimidyl, N-succinimidyloxy, N-phthalimidyloxy, N-(5-norbornen-2,3-dicarboxyimidyloxy), 2-thioxothiazolidine-3-yl, —ON═(CN)R, 2-pyridyloxy, phenoxy, p-chlorophenoxy, p-nitrophenoxy, trichlorophenoxy, and pentachlorophenoxy, and

wherein R is an alkyl group or an aryl group.

6. The compound according to claim 5 , wherein Y is selected from the group consisting of N-succinimidyloxy, 1-benzotriazolyloxy, N-phthalimidyloxy, N-(5-norbornen-2,3-dicarboxyimidyloxy), p-nitrophenoxy, 2-thioxothiazolidine-3-yl, and imidazolyl.

7. The compound according to claim 6 , wherein Y is N-succinimidyloxy.

8. The compound according to claim 1 , wherein X is selected from the group consisting of O and NH.

9. The compound according to claim 8 , wherein X is O.

10. The compound according to claim 1 , wherein n is 1.

11. The compound according to claim 1 , wherein n is 2.

12. A compound selected from the group consisting of 4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 4-(2-methoxypolyethoxy)-2-methylbutanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 4-(2-methoxypolyethoxy)-2,2-dimethylbutanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 5-(2-methoxypolyethoxy)-2,2-dimethylpentanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 6-(2-methoxypolyethoxy)-2,2-dimethylhexanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 2-ethyl-5-(2-methoxypolyethoxy)pentanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 5-(2-methoxypolyethoxy)-2-propylpentanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 2-(2-(2-methoxyethoxy)ethyl)hexanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 3-(2-methoxypolyethoxy)-2,2-dimethylpropanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 2(2-methoxypolyethoxy)methyl)-2-methylbutanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 2-ethyl-2-((2-methoxypolyethoxy)methyl)butanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 2(2-methoxypolyethoxy)methyl)-2-methylpentanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 2(2-methoxypolyethoxy)methyl)-2-propylpentanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 2(2-methoxypolyethoxy)methyl)-3-methylbutanoate;

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 2(2-methoxypolyethoxy)methyl)hexanoate; and

4-(((2,5-dioxopyrrolidin-l-yloxy)carbonyloxy)methyl)phenyl 3-(2-methoxyethoxy)-2-methylpropanoate.

13. A drug conjugate of Formula II:

wherein X is selected from the group consisting of O, S and NR 3 ;

n is 1or 2;

POLYMER is a water soluble, non-peptidic polymer wherein POLYMER does not comprise a poly(alkylene glycol);

R 1 , and R 2 , are independently selected from the group consisting of hydrogen, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkylenearyl, and aryl with the proviso that at least one of R 1 , and R 2 , is different from hydrogen;

R 3 , is selected from the group consisting of hydrogen, (C 1 -C 6 ) -alkyl, (C 1 -C 6 ) -alkylenearyl, and aryl; and

DRUG is an amino-containing molecule, peptide, or protein, or a pharmaceutically acceptable salt, ester, or solvate thereof.

14. The drug conjugate according to claim 13 , wherein DRUG is a plasma protein or a blood coagulation factor.

15. The drug conjugate according to claim 14 , wherein DRUG is selected from the group consisting of erythropoietin, Factor H, Factor VIII, von Willebrand Factor, Factor VIIa, and Factor IX.

16. The drug conjugate according to claim 14 , wherein DRUG is Factor VIII.

17. A pharmaceutical formulation comprising the drug conjugate of claim 13 and a pharmaceutically acceptable excipient.

18. The pharmaceutical formulation of claim 17 , wherein the formulation is encapsulated in a microparticle.

19. The compound according to claim 1 , selected from the group consisting of:

20. The compound according to claim 19 , wherein POLYMER is polysialic acid.

21. The compound of claim 20 , having a structure

22. The compound of claim 20 , having a structure

23. The compound of claim 20 , having a structure

24. The compound of claim 20 , having a structure

25. The compound of claim 20 , having a structure

26. The compound of claim 20 , having a structure

27. The compound of claim 20 , having a structure

28. The compound of claim 20 , having a structure

29. The compound of claim 20 , having a structure

30. The compound of claim 20 , having a structure

31. The compound of claim 20 , having a structure

32. A compound having a structure selected from the group consisting of

wherein POLYMER is polysialic acid.

33. A compound of Formula I:

wherein Y is an activating group;

X is selected from the group consisting of O, S and NR 3 ;

n is 1or 2;

POLYMER is a water soluble, non-peptidic polymer wherein POLYMER comprises a poly(alkylene glycol);

R 1 , is hydrogen;

R 2 , is selected from the group consisting of (C 1 -C 6 ) -alkyl, (C 1 -C 6 ) -alkylenearyl, and aryl; and

R 3 , is selected from the group consisting of hydrogen, (C 1 -C 6 ) -alkyl, (C 1 -C 6 ) -alkylenearyl , and aryl.

34. The compound according to claim 33 , wherein the poly(alkylene glycol) comprises poly(ethylene glycol) (PEG).

35. The compound according to claim 34 , wherein the PEG has a molecular weight of about 200, to about 500,000.

36. The compound according to claim 33 , wherein R 2 , is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl and n-butyl.

37. The compound according to claim 33 , wherein Y is selected from the group consisting of N-succinimidyloxy, 1-benzotriazolyloxy, N-phthalimidyloxy, N-(5-norbornen-2,3-dicarboxylmidyloxy), p-nitrophenoxy, 2-thioxothiazolidine-3-yl, and imidazolyl.

38. The compound according to claim 33 , selected from the group consisting of:

39. A drug conjugate of Formula II:

X is selected from the group consisting of O, S and NR 3 ;

n is 1or 2;

POLYMER is a water soluble, non-peptidic polymer wherein POLYMER comprises a poly(alkylene glycol);

R 1 is hydrogen;

R 2 is selected from the group consisting of (C 1 -C 6 ) -alkyl, (C 1 -C 6 ) -alkylenearyl, and aryl;

R 3 is selected from the group consisting of hydrogen, (C 1 -C 6 ) -alkyl, (C 1 -C 6 ) -alkylenearyl, and aryl; and

DRUG is an amino-containing molecule, peptide, or protein, or a pharmaceutically acceptable salt, ester, or solvate thereof.

40. The drug conjugate according to claim 39 , wherein DRUG is a plasma protein or a blood coagulation factor.

41. The drug conjugate according to claim 40 , wherein DRUG is selected from the group consisting of erythropoietin, Factor H, Factor VIII, von Willebrand Factor, Factor VIIa, and Factor IX.

42. The drug conjugate according to claim 40 , wherein DRUG is Factor VIII.

43. A pharmaceutical formulation comprising the drug conjugate of claim 39 and a pharmaceutically acceptable excipient.

44. The pharmaceutical formulation of claim 43 , wherein the formulation is encapsulated in a microparticle.